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Purpose: The role of SRY-Box 2 (SOX2) in anophthalmia/microphthalmia (A/M) is well known, with 10%–20% of A/
M explained by mutations in SOX2. SOX2 plays roles in the development of both the posterior and anterior segment
structures of the eye and relies on interactions with tissue-specific partner proteins to execute its function, raising the
possibility that SOX2 mutations may result in varying ocular phenotypes. Recent data has identified a missense mutation
in SOX2 in an extended pedigree with phenotypes as varied as A/M, isolated iris hypoplasia, iris and chorioretinal
coloboma, pupil defects, and hypermetropia, suggesting a broader phenotypic spectrum associated with SOX2 mutations.
Methods: Screening of SOX2 was completed in 89 patients with a variety of ocular anomalies, including 28 with A/M
and 61 with normal eye size and anterior segment dysgenesis (28), cataract (14), isolated coloboma (5), or other eye
disorders (14).
Results: The recurrent de novo frameshift mutation c.70del20 was identified in one patient with microphthalmia and
syndromic anomalies consistent with SOX2 anophthalmia syndrome; the mutation frequency in our A/M population (4%)
was lower than previously reported; it is likely that extensive utilization of clinical SOX2 testing has led to a bias toward
SOX2-negative A/M cases in our research cohort. No disease-causing mutations were identified in patients with non-
microphthalmia phenotypes.
Conclusions: The recurrent c.70del20 mutation accounts for 21% of all independent SOX2 mutations reported to date.
Due to the increased use of clinical SOX2 testing, the frequency of SOX2 mutations identified in research A/M populations
will likely continue to decrease. Mutations in SOX2 do not appear to be a common cause of ocular defects other than
anophthalmia/microphthalmia.
SOX2 is a High Mobility Group (HMG) DNA binding
domain-containing transcription factor with a well established
role  as  a  common  cause  of  dominant  anophthalmia/
microphthalmia (A/M). SOX2/Sox2 expression begins early
in  eye  development  and  is  critical  for  the  formation  of
different  ocular  tissues  [1-4].  In  mice,  Sox2  is  expressed
within the optic vesicle and stalk, the developing neural retina,
the placodal area of the surface ectoderm, and throughout lens
development starting with the lens placode and continuing
through differentiating lens fibers [1,2,4]. Studies of human
fetal  tissues  are  consistent  with  the  mouse  data;  SOX2
expression is seen in the developing neural retina and optic
stalk as well as during all stages of lens development [3].
SOX proteins typically contain three functional domains:
the High Mobility Group (HMG) domain that is responsible
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for DNA binding, an activation or repression domain, and a
partner-factor  interaction  domain.  SOX2,  like  other  SOX
proteins,  requires  interaction  with  partner  factors  to
successfully regulate target genes, likely due to low-affinity
DNA-binding by SOX proteins alone [5]. Partner factors bind
to the regulatory sequence near the site of SOX binding and
also interact with the SOX protein, thus forming a ternary
complex. This complex stabilizes the interaction between the
SOX  protein  and  DNA  and  allows  specific  regulation  of
diverse target genes [5]. For example, SOX2 has been shown
to partner with  δ-crystallin enhancer factor 3 (δEF3) as well
as  paired  box  gene  6  (PAX6)  to  activate  δ-crystallin
expression during lens formation [6,7] and with octomer-
binding transcription factor 3/4 (Oct3/4) to regulate fibroblast
growth factor 4 (FGF4) or undifferentiated embryonic cell
transcription factor 1 (UTF1) target genes in embryonic stem
cells [5]. Thus, depending on the affected site/domain, it is
possible that some SOX2 mutations may affect certain protein
interactions more than others and therefore result in variable
and tissue-specific phenotypes.
Molecular Vision 2010; 16:768-773 <http://www.molvis.org/molvis/v16/a86>
Received 2 January 2010 | Accepted 21 April 2010 | Published 28 April 2010
© 2010 Molecular Vision
768Mutations  in  SOX2  account  for  10%–20%  of  A/M
[8-11].  Individuals  with  SOX2  mutations  often  have
associated systemic anomalies, termed SOX2 anophthalmia
syndrome,  consisting  of  ocular,  brain,  pituitary,
genitourinary, and gastresophageal anomalies, although eye
defects can be isolated as well [8-11]. The anophthalmia/
microphthalmia phenotype in patients with SOX2 mutations
can be bilateral, unilateral, or, occasionally, absent; 14 of the
71  individuals  reviewed  previously  [11]  or  subsequently
reported [12] do not have anophthalmia/microphthalmia of
either  eye.  Severe  SOX2  mutations  (whole  gene  deletion/
nonsense)  which  most  likely  produce  complete  loss-of-
function  alleles  almost  uniformly  result  in  anophthalmia/
microphthalmia (47 out of 50 cases [11]), suggesting that
these  mutations  result  in  a  major  disruption  of  eye
development, while missense mutations are more likely to be
associated with non-microphthalmia phenotypes (11 of 21
cases [11,12]).
Several  families  with  missense  mutations  and  non-
microphthalmia phenotypes have been previously reported
including two probands with optic nerve hypoplasia and their
unaffected  fathers  [13],  a  father  and  son  with  iris  and
chorioretinal uveal colobomas [14], and, more recently, a
large  four-generation  pedigree  with  diverse  phenotypes,
including microphthalmia in some individuals [12]. The latest
report describes a mutation in a four-generation pedigree that
results in the substitution of a highly conserved amino acid
within  the  partner-factor  interaction  region  of  the  SOX2
protein and is the first mutation reported in this domain. While
the proband was affected with bilateral anophthalmia, the
other  eight  family  members  carrying  the  mutation  were
affected with milder ocular phenotypes. Five of the affected
individuals did not have anophthalmia or microphthalmia.
The  proband’s  mother  had  bilateral  iris  and  chorioretinal
colobomata, the maternal aunt was found to have a small
inferior retinal tuft in one eye along with hypermetropia and
astigmatism, and the proband’s brother was affected with
hypermetropia only. Finally, the maternal grandmother was
affected  with  iris  hypoplasia  and  hypermetropia  while  a
maternal great-aunt had microcornea only. In addition to the
two cases above with isolated anterior segment defects (iris
hypoplasia and microcornea), two individuals demonstrated
anterior segment defects (posterior embryotoxon and an iris
pupillary defect) in the presence of microphthalmia, further
suggesting  that  SOX2  plays  a  role  in  anterior  segment
development. Several family members who did not carry the
mutation had normal eye examinations [12].
As  discussed  above,  the  variability  of  phenotypes
associated with, in particular, missense changes in SOX2 may
be  explained  by  the  fact  that  these  mutations  result  in
alteration  of  its  interactions  with  tissue-specific  protein
partners rather than a complete loss-of-function [5,12-14]. In
addition to this, the genetic makeup of these partner factors,
other ocular development genes, or yet unknown factors are
likely  to  play  role  in  the  phenotypic  expression  of  SOX2
mutations.  Since  expression  during  lens  development
represents an important site of SOX2 activity, it is possible
that some mutations may lead to phenotypes associated with
specific loss of SOX2-related activity in the lens, such as
cataracts and anterior segment defects.
Mutations in SOX2 may result in a broader phenotypic
spectrum consistent with its role in both posterior and anterior
segment development and dependent on the affected partner
interaction domain. The role of SOX2 in A/M has been well
characterized while its potential involvement in other eye
conditions has not yet been investigated. To further explore
the role of SOX2 in variable ocular diseases, we undertook
screening of this gene in our population of patients with a
variety of ocular defects.
METHODS
This human study was approved by the Institutional Review
Boards  of  Children's  Hospital  of  Wisconsin  and  Albert
Einstein  Healthcare  Network.  Cases  were  identified  and
clinical data collected through the Genetic Studies of Human
Developmental  Disorders  at  the  Medical  College  of
Wisconsin, Milwaukee, WI or the A/M Clinical Registry at
the  Albert  Einstein  Medical  Center,  Philadelphia,  PA.
TABLE 1. SUMMARY OF OCULAR CONDITIONS AND SOX2 MUTATIONS REPORTED IN THIS STUDY.
Ocular condition Number of cases Bilateral Syndromic Number of mutations
Anophthalmia 8 6/8 6/8 0
Microphthalmia 20 11/20 11/20 1
A/M total 28 17/28 17/28 1/28
Anterior segment dysgenesis 28 22/28 20/28 0
Cataract 14 14/14 1/14 0
High myopia 6 6/6 0/6 0
Coloboma (isolated) 5 3/5 0/5 0
Glaucoma 4 4/4 2/4 0
Other eye defect 4 4/4 4/4 0
Non-A/M total 61 53/61 27/61 0/61
Total number 89 70/89 44/89 1/89
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769Genomic DNA was extracted using the Autopure LS system
(Qiagen, Valencia, CA) from blood or buccal samples and
the SOX2   coding region was amplified using  primers:  set  1
forward, 5'-AGT CCC GGC CGG GCC GAG-3', and set 1
reverse, 5'-GGT AGC CCA GCT GGT CCT G-3', and set 2
forward, 5'-CAA GAC GCT CAT GAA GAA GG-3', and set
2 reverse, 5'-TAC TCT CCT CTT TTG CAC CC-3'. PCR
products were sequenced in both directions using Big Dye
Terminator v3.1 (Applied Biosystems, Foster City, CA) with
3730XL DNA Analyzer (Applied Biosystems, Foster City,
CA).  Chromatograms  were  examined  manually  and  using
Mutation Surveyor software (SoftGenetics, State Collge, PA).
All initially identified changes were confirmed by additional
independent PCR and sequencing experiments.
The  screening  included  89  patients  with  a  variety  of
ocular  disorders  (Table  1).  Twenty-eight  patients  were
affected with anophthalmia/microphthalmia (17 bilateral, 17
syndromic). An additional 28 patients had anterior segment
dysgenesis (22 bilateral, 20 syndromic); eight of these patients
were specifically noted to have iris hypoplasia (two with full
Axenfeld-Rieger syndrome), four were noted to have pupil
anomalies, 11 had Peters’ anomaly (one with iris coloboma in
addition), and the remaining five had other anterior segment
defects.  There  were  five  patients  with  isolated  coloboma
(three were iris and chorioretinal). Finally, six patients had
isolated high myopia, four patients had glaucoma with no
other ocular anomalies (three congenital, one adult-onset), 14
had cataract with no other ocular anomalies (11 congenital,
two juvenile, and one adult-onset), and the remaining four had
other eye defects (including microspherophakia, Septo-optic
dysplasia, and Morning Glory disc anomaly).
Paired homeodomain transcription factor 2 (PITX2) was
previously screened in 26 of the 28 patients with anterior
segment dysgenesis with no mutations identified. Forkhead
box E3 (FOXE3) was previously screened in 20 of the 28
patients with anterior segment dysgenesis (including 9 of 11
with  Peters’  anomaly)  with  no  mutations  identified.  Two
patients with mutations in SOX2 identified via clinical testing
were  known  to  decline  enrollment  in  this  research  study
during this period of patient recruitment.
RESULTS AND DISCUSSION
Screening of these 89 patients identified a disease-causing
mutation in one patient. The recurrent frameshift mutation in
SOX2,  c.70del20,  was  identified  in  Patient  1  of  African
American decent who was affected with microphthalmia and
optic nerve hypoplasia in the right eye but had a normal left
eye;  in  addition  to  ocular  defects,  the  patient  displayed
micropenis,  cryptorchidism,  prostatic  utricle,  pancreatic
deficiency, low-set prominent ears, umbilical hernia, feeding
disorder,  and  global  developmental  delay,  consistent  with
SOX2 anophthalmia syndrome (Figure 1A,B). This mutation
is predicted to result in a frameshift and truncation of normal
SOX2 protein at amino acid 23 (7% of its total length), before
the HMG DNA-binding domain. The parents of Patient 1 are
unaffected  and  were  found  to  carry  normal  SOX2  alleles
consistent with the de novo phenotype observed in their child
(Figure 1B). The recurrent c.70del20 mutation has now been
Figure 1. Identification of a c.70del20 mutation in a patient with unilateral microphthalmia. A: Photograph of Patient 1 with SOX2 anophthalmia
syndrome. Note right microphthalmia (prosthesis in place) and prominent ears. B: Sequence fragments showing the c.70del20 region in the
patient (p), his mother (m) and his father (f). The position of the deletion is indicated with a red arrow. Note normal SOX2 sequence in the
patient’s parents consistent with their unaffected status.
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770reported  in  eleven  patients  from  ten  unrelated  pedigrees,
typically resulting in a severe phenotype characterized by
bilateral  anophthalmia/microphthalmia  and  systemic
anomalies  (Table  2).  The  family  reported  in  this  study
represents  only  the  second  case  of  unilateral  eye  defects
associated  with  the  c.70del20  mutation;  the  previously
described pedigree includes a patient with unilateral ocular
phenotype and a sibling with normal eyes bilaterally [15].
Also, to the best of our knowledge, this is the first reported
occurrence of the c.70del20 mutation in an African American
patient, but several previous reports did not include race/
ethnicity data. The c.70del20 mutation appears to be the major
recurrent mutation in SOX2; one other mutation, c.529C>T,
has been noted in three unrelated families [8,13] while the
remaining 34 reported mutations are unique [11]. Two similar
deletions,  a  17-base  pair  deletion  at  the  same  nucleotide
position, and a 23-base pair deletion in the codon before, have
each  been  reported  in  one  family  [9,16].  Slipped-strand
mispairing has been implicated as the likely mechanism of this
recurrent mutation due to the presence of a GGCGGC repeat
sequence flanking the region [17]. These 17 to 23-base pair
deletions account for 25% of all SOX2 mutations in probands
(12/48)  with  the  c.70del20  mutation  contributing  21%
(10/48). This warrants special attention to this region in A/M
patients being evaluated for SOX2 mutations.
The frequency of SOX2 mutations within our population
of patients with anophthalmia/ microphthalmia (1/28=4%)
was much lower than has been previously reported [8-11],
likely due to increased clinical testing of SOX2 in affected
patients before enrollment in a research study. If the two
patients known to have a clinically identified mutation in
SOX2  are  included,  the  frequency  of  SOX2  mutations
increases to 10% (3/30), which is consistent with previous
reports. Given the well known role of SOX2 in anophthalmia/
microphthalmia, the easily recognizable associated features,
and the availability of clinical sequencing, it seems likely that
many physicians may order clinical testing before referring a
family  to  a  research  study.  Thus,  the  frequency  of  SOX2
TABLE 2. CLINICAL FINDINGS IN PATIENTS WITH THE RECURRENT C.70DEL20 MUTATION IN SOX2.
Reported case 1 2 3 (sibling) 4 5 6 7 8 9 10 11
Right Eye AN NOR NOR MI AN AN AN MI AN AN MI, ONH
Left Eye AN AN NOR AN ASD, CA,
COL, GL
AN AN MI AN AN NOR
Other
Anomalies
Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes
Reference [17] [15] [15] [12] [10] [10] [3] [11] [11] [11] This study
The reported cases are numbered based upon date of publication. In the table AN indicates Anophthalmia; MI indicates
Microphthalmia; ASD indicates Anterior segment dysgenesis; CA indicates Cataract; COL indicates Coloboma; GL indicates
Glaucoma; NOR indicates Normal; and ONH indicates Optic nerve hypoplasia.
Figure 2. Schematic drawing of the SOX2 protein with mutations indicated. Mutations resulting in A/M phenotype (unilateral or bilateral)
are shown on the top while mutations resulting in non-microphthalmia phenotypes (bilateral) are indicated below; missense mutations are
indicated with asterisks. Each specific mutation is marked with a single arrow, unless the mutation resulted in both A/M and non-A/M ocular
phenotypes, in which case the mutation is marked with an arrow above and below. Recurrent mutations are indicated with longer arrows with
the number of families listed above. The dark gray box represents the homeodomain and the light gray box a partner-factor interaction domain.
In the image, NOR indicates Normal; PU indicates Pupillary abnormality; MC indicates Microcornea; CA indicates Cataract; COL indicates
Coloboma; CR indicates Chorioretinal dystrophy; ET indicates Esotropia; MY indicates High myopia; IH indicates Iris hypoplasia; ONH
indicates Optic nerve hypoplasia.
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771mutations observed in current and future research populations
will likely be significantly lower than the actual frequency of
mutations in A/M.
Previously reported mutations in SOX2 associated with
A/M or non-A/M phenotypes are scattered throughout the
gene  with  no  particular  pattern  identified  (Figure  2).  No
disease-causing mutations were identified in 61 patients with
ocular anomalies other than anophthalmia/microphthalmia,
including 20 with phenotypes which specifically match those
seen  in  the  family  reported  by  Mihelec  et  al.  [12]:  iris
hypoplasia,  pupil  anomalies,  coloboma,  and  optic  nerve
hypoplasia. In all, 28 patients with anterior segment anomalies
and an additional five patients with coloboma were screened
with  no  disease-causing  mutations  identified.  The  SOX2
sequence appears to be extremely conserved with only one
synonymous  polymorphism  (c.453G>A)  observed  in  our
patient group (also seen in controls).
Our data suggests that SOX2 mutations are not a common
cause  of  ocular  defects  other  than  anophthalmia/
microphthalmia.  Further  studies  with  larger  numbers  of
different phenotypes may reveal additional mutations, but
there  is  no  evidence  at  this  time  to  suggest  that  routine
screening of SOX2 in patients with other ocular phenotypes is
warranted.
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